Postmenopausal metabolic syndrome
Conditions
Interventions
Group 1 :Modified Zexie Decoction granules
Group 2:modified Zexie Decoction decoction pieces
Group 3:Modified Zexie Decoction granules placebo group
Sponsors
The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincal Hospital of Chinese Medicine)
Eligibility
Sex/Gender
Female
Age
41 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Meet the diagnostic criteria of metabolic syndrome: 3 out of 5 items: TG >= 150 mg/dl (1.7 mmol/l); Hdl-c = 6.1 mmol/L or 2 hours after glucose loading >= 7.8 mmol/L; Elevated blood pressure: systolic blood pressure >= 130 mmHg or diastolic blood pressure >= 85 mmHg, or treated with antihypertensive drugs; Waist circumference >= 85 cm; 2. Women aged 41-60 years; 3. Meet the above diagnostic criteria, and the risk factors are in the following range: TC: 5.18-6.19 mmol/L; LDL-C: 3.37-4.12 mmol/L; TG: 1.70-2.25 mmol/L; Blood sugar level < 7.0 mmol/L; Systolic blood pressure <= 150 mmHg or diastolic blood pressure <= 95 mmhg; BMI <= 35 4. Patients with cardiovascular risk less than 10% in 10 years (using China-PAR risk assessment calculator); 5. TCM syndrome differentiation belongs to qi deficiency and dampness stagnation syndrome; 6. Climacteric syndrome kupperman index (ki) < 15; 7. No other drugs for the treatment of metabolic syndrome have been used in the past 4 weeks; No hormone therapy, selective estrogen receptor modulators, aromatase inhibitors, soybean extracts or herbs have been used; 8. Voluntary and capable of signing informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with secondary dyslipidemia and familial hypercholesterolemia or secondary hypertension; 2. Patients with unstable angina pectoris, acute myocardial infarction, coronary stent implantation or coronary artery bypass surgery are at high risk of coronary heart disease; 3. Patients with a 10-year cardiovascular risk >= 10%(using china-PAR Risk Assessment Calculator); 4. Patients with type 1 diabetes with a history of diabetes > 10 years and concomitant kidney disease or other cardiovascular disease risk factors; 5. Patients with carotid artery stenosis, transient ischemic attack, acute stroke and peripheral vascular disease; 6. Patients with severe liver and renal insufficiency, hematopoietic system, malignant tumors and other serious primary diseases; 7. Psychiatric patients (schizophrenia, mania, paranoid psychosis and depression with significant suicidal tendencies); 8. Patients addicted to alcohol or other related products; 9. Patients who has participated in phase I and II clinical trials within the past 6 months or has participated in phase III and IV clinical trials within 3 months; 10. Patients with allergic constitution, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| glycometabolism;lipid metabolism;blood pressure;Physical examination (body weight, abdominal circumference, etc.);Body composition analysis; | — |
Secondary
| Measure | Time frame |
|---|---|
| carotid color ultrasonography;Homocysteine;C reactive protein;Metabonomics;gut microbiota; | — |
Countries
China
Contacts
Public ContactGuangning Nie
The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincal Hospital of Chinese Medicine)
Outcome results
None listed